Quick Answer
Vistagen Therapeutics, Inc. reported Stockholders Equity of $70.39 million for fiscal year 2025.
Vistagen Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $70.39M | -38.4% |
| 2024 | $114.29M | +846.1% |
| 2023 | $12.08M | -81.3% |
| 2022 | $64.72M | -29.6% |
| 2021 | $91.98M | +1705.4% |
| 2020 | -$5.73M | -181.0% |
| 2019 | $7.08M | +2.3% |
| 2018 | $6.92M | +1023.2% |
| 2017 | $615.8K | +120.7% |
| 2016 | -$2.98M | +85.5% |
| 2015 | -$20.54M | -60.5% |
| 2014 | -$12.80M | -1.9% |
| 2013 | -$12.56M | -120.1% |
| 2012 | -$5.71M | +82.6% |
| 2011 | -$32.88M | -24.9% |
| 2010 | -$26.34M | +1.3% |
| 2009 | -$26.68M | -20.4% |
| 2008 | -$22.17M | -27.0% |
| 2007 | -$17.45M | -5.7% |
| 2006 | -$16.50M | -12.0% |
| 2005 | -$14.74M | -7.7% |
| 2004 | -$13.69M | -176.7% |
| 2003 | -$4.95M | -7.9% |
| 2002 | -$4.58M | -82.5% |
| 2001 | -$2.51M | -197.5% |
| 2000 | -$844.1K | -274.3% |
| 1999 | -$225.5K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $50.92M | -37.2% | -23.2% |
| September 30, 2025 | $66.34M | -28.6% | +16.9% |
| June 30, 2025 | $56.77M | -45.8% | -19.4% |
| March 31, 2025 | $70.39M | -38.4% | -13.2% |
| December 31, 2024 | $81.12M | -34.2% | -12.7% |
| September 30, 2024 | $92.97M | +160.8% | -11.3% |
| June 30, 2024 | $104.80M | +1430.2% | -8.3% |
| March 31, 2024 | $114.29M | +846.1% | -7.3% |
- Vistagen Therapeutics, Inc. showed a decrease of -38.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 1999–2025 period, Vistagen Therapeutics, Inc.’s stockholders equity has grown by 31315.1% (from -$225.5 thousand to $70.39 million).
- The most recent figure is from Vistagen Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: